Last reviewed · How we verify

Td1aP — Competitive Intelligence Brief

Td1aP (Td1aP) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine (toxoid and acellular). Area: Immunology / Infectious Disease.

marketed Vaccine (toxoid and acellular) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Td1aP (Td1aP) — Swedish Institute for Infectious Disease Control. Td1aP is a combined diphtheria-tetanus-acellular pertussis vaccine that stimulates immune responses against three bacterial pathogens.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Td1aP TARGET Td1aP Swedish Institute for Infectious Disease Control marketed Vaccine (toxoid and acellular)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vaccine (toxoid and acellular) class)

  1. Swedish Institute for Infectious Disease Control · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Td1aP — Competitive Intelligence Brief. https://druglandscape.com/ci/td1ap. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: